Husum YS, Moe MC, Bragadóttir R, et al. - In this retrospective observational study, researchers sought to compare outcomes of a treatment algorithm that allows for switching treatment‐resistant neovascular age‐related macular degeneration (nAMD) eyes to aflibercept with continuing bevacizumab. The study involved 40 eyes from 2012 and 88 eyes from 2018. According to the findings, switching eyes with treatment-resistant nAMD to aflibercept provides a modest visual advantage as compared with continuing first-line bevacizumab therapy.